Nanoliposomes as nonviral vectors in cancer gene therapy

Basit Öğe Kaydı
dc.authorscopusidAli Zarrabi / 23483174100
dc.authorwosidAli Zarrabi / GSA-3718-2022
dc.contributor.authorYıldız, Safiye Nur
dc.contributor.authorEntezari, Maliheh
dc.contributor.authorPaskeh, Mahshid Deldar Abad
dc.contributor.authorMirzaei, Sepideh
dc.contributor.authorKalbasi, Alireza
dc.contributor.authorZabolian, Amirhossein
dc.contributor.authorHashemi, Farid
dc.contributor.authorHushmandi, Kiavash
dc.contributor.authorHashemi, Mehrdad
dc.contributor.authorRaei, Mehdi
dc.contributor.authorGoharrizi, Mohammad Ali Sheikh Beig
dc.contributor.authorAref, Amir Reza
dc.contributor.authorZarrabi, Ali
dc.contributor.authorRen, Jun
dc.contributor.authorOrive, Gorka
dc.contributor.authorRabiee, Navid
dc.contributor.authorErtaş, Yavuz Nuri
dc.date.accessioned2025-04-18T10:02:11Z
dc.date.available2025-04-18T10:02:11Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümü
dc.description.abstractNonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off-targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions. © 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
dc.description.sponsorshipThis study was supported by T\u00FCrkiye Bilimsel ve Teknolojik Ara\u015Ftirma Kurumu, (118C346).
dc.identifier.citationYildiz, S. N., Entezari, M., Paskeh, M. D. A., Mirzaei, S., Kalbasi, A., Zabolian, A., ... & Ertas, Y. N. (2024). Nanoliposomes as nonviral vectors in cancer gene therapy. MedComm, 5(7), e583.
dc.identifier.doi10.1002/mco2.583
dc.identifier.issn26882663
dc.identifier.issue7
dc.identifier.scopus2-s2.0-85196831643
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1002/mco2.583
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6926
dc.identifier.volume5
dc.identifier.wosWOS:001274057600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorZarrabi, Ali
dc.institutionauthoridAli Zarrabi / 0000-0003-0391-1769
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofMedComm
dc.relation.publicationcategoryDiğer
dc.relation.tubitak118C346
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCRISPR/Cas9
dc.subjectLiposome
dc.subjectNonviral Vector
dc.subjectShRNA
dc.subjectSiRNA
dc.titleNanoliposomes as nonviral vectors in cancer gene therapy
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Biyomedikal Mühendisliği Bölümü Diğer Yayınlar Koleksiyonu